Cap: $1.43B
Runway: Q2 2028
Clinical Pipeline (Compendium View)
| Asset | Indication | Stage | Next Catalyst |
|---|---|---|---|
| VIR-5500 | mCRPC (Prostate Cancer) | Phase 1 (Updating to Pivotal) | Astellas Deal Close: April 2026 |
| Tobevibart + Elebsiran | Chronic Hepatitis D (HDV) | Phase 2 (ECLIPSE) | Full Enrollment: Q2 2026 |
Latest SEC Filings
Active Clinical Trials
Operational Overview
Operational Overview
Vir has undergone a massive transformation from a COVID-focus to an IO (Immuno-Oncology) and HDV powerhouse. The $1.7B Astellas partnership signed in Feb 2026 has completely de-risked their prostate cancer program.
Financial Fortitude
With nearly $900M in total pro-forma cash, VIR is the “Giant” in this coverage list. They are moving directly from Phase 1 to Pivotal trials in 2027 for VIR-5500, a bold move that signals high confidence in their “masked” T-cell engager platform.